Knight Therapeutics Inc to Post Q1 2019 Earnings of $0.03 Per Share, Cormark Forecasts (GUD)

Knight Therapeutics Inc (TSE:GUD) – Equities researchers at Cormark increased their Q1 2019 earnings estimates for shares of Knight Therapeutics in a report issued on Thursday, February 21st. Cormark analyst T. Gonsalves now anticipates that the company will post earnings of $0.03 per share for the quarter, up from their previous forecast of $0.02. Cormark also issued estimates for Knight Therapeutics’ FY2019 earnings at $0.12 EPS.

Several other analysts have also recently weighed in on the company. Raymond James reissued an “outperform” rating and set a C$10.25 price target on shares of Knight Therapeutics in a report on Wednesday, January 16th. Bloom Burton reissued an “accumulate” rating on shares of Knight Therapeutics in a report on Friday, November 9th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Knight Therapeutics currently has a consensus rating of “Buy” and a consensus target price of C$10.06.

Shares of TSE GUD opened at C$7.60 on Friday. The company has a market cap of $1.09 billion and a PE ratio of 35.02. Knight Therapeutics has a 12 month low of C$7.49 and a 12 month high of C$8.81.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Further Reading: How to read a candlestick chart

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit